Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: A systematic review
| Autor: | Brigida Anna Maiorano, Anna Acampora, Jacopo Romagnoli, Ilaria Esposito, Laura Del Regno, Giovanni Schinzari, Giampaolo Tortora, Alessandro Di Stefani, Luca Tagliaferri, Valentina Lancellotta, Ketty Peris, Bruno Fionda, Ernesto Rossi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Oncology
PD-L1 Graft Rejection medicine.medical_specialty medicine.medical_treatment Immune checkpoint inhibitors Immunology Programmed Cell Death 1 Receptor Antineoplastic Agents Disease Antineoplastic Agents Immunological Internal medicine melanoma Immunology and Allergy Medicine Humans Immune Checkpoint Inhibitors Kidney transplantation Response rate (survey) CTLA4 biology business.industry Melanoma Cancer Immunotherapy renal transplantation medicine.disease Kidney Transplantation Transplant Recipients PD1 Immunological biology.protein immunotherapy rejection business Settore MED/35 - MALATTIE CUTANEE E VENEREE checkpoint inhibitors |
| Popis: | Kidney transplantation leads to an increased risk of cancer. Melanoma is one of the most frequent neoplasms in kidney transplant recipients. Transplanted patients were excluded from trials with checkpoint inhibitors in melanoma. The authors performed a systematic review regarding the use of anti-PD1 and anti-CTLA4 agents in renal transplanted patients with melanoma. Thirty-four cases were included (24 progressive disease, eight partial responses and one stable disease) but no complete response were reported. Fourteen graft rejections were observed, especially with anti-PD1 agent. The median time from the start of immune-checkpoint inhibitor and rejection was 21 days. Response rate was similar between patients with rejection and patients without rejection. The benefit of immune-checkpoint inhibitors versus the risk of allograft rejection should be carefully weighted for each patient. A multidisciplinary approach should be considered to discuss the most appropriate treatment for every case, given the aggressiveness of melanoma in these subsets of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|